NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.020
0.00 (0.00%)
At close: Sep 11, 2026, 4:00 PM EDT
1.030
+0.010 (0.98%)
After-hours: Sep 11, 2026, 8:00 PM EDT
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,155,856
Market Cap
23.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Evaxion | 46 |
| Jasper Therapeutics | 22 |
| ABVC BioPharma | 19 |
| Lantern Pharma | 16 |
| Atossa Therapeutics | 16 |
| Tvardi Therapeutics | 12 |
| Cellectar Biosciences | 11 |
NNVC News
- 4 days ago - NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus - TheFly
- 4 days ago - Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo - Accesswire
- 12 days ago - NanoViricides provides updateon Measles Drug Treatment Program - TheFly
- 12 days ago - While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - Accesswire
- 21 days ago - NanoViricides registers to sell 2.52M shares of common stock for holders - TheFly
- 25 days ago - NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’ - TheFly
- 25 days ago - The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon - Accesswire
- 4 weeks ago - NanoViricides receives regulatory approval for Phase II trial of NV-387 - TheFly